<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02001623</url>
  </required_header>
  <id_info>
    <org_study_id>GEN701</org_study_id>
    <secondary_id>innovaTV 201</secondary_id>
    <nct_id>NCT02001623</nct_id>
  </id_info>
  <brief_title>Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors</brief_title>
  <official_title>First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed&#xD;
      population of patients with specified solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is conducted in two parts. The dose escalation portion of the trial subjects are&#xD;
      enrolled into cohorts at increasing dose levels of HuMax-TF-ADC in 21 day treatment cycles.&#xD;
&#xD;
      In the Cohort Expansion part of the trial, will further explore the recommended phase 2 dose&#xD;
      of HuMax-TF-ADC as determined in Part 1&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2013</start_date>
  <completion_date type="Actual">May 2, 2019</completion_date>
  <primary_completion_date type="Actual">May 2, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Escalation phase for dose finding followed by expansion phase</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events measured throughout the study from first treatment until end of trial.</measure>
    <time_frame>After first treatment cycle (3 weeks) and at end of trial (an expected average of 6 months)</time_frame>
    <description>As this is a phase I trial the main objective is to assess the safety and tolerability of HuMax-TF-ADC throughout the treatment periods of the patients participating in the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile of HuMax-TF-ADC after single and multiple infusions</measure>
    <time_frame>After first treatment cycle (3 weeks) and at end of trial (an expected average of 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of HuMax-TF-ADC; tumor size (RECIST), PSA and/or CA-125</measure>
    <time_frame>At end of trial (an expected average of 6 months)</time_frame>
    <description>Evaluate the anti-tumor activity of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Ovary Cancer</condition>
  <condition>Cervix Cancer</condition>
  <condition>Endometrium Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Prostate Cancer (CRPC)</condition>
  <condition>Esophagus Cancer</condition>
  <condition>Lung Cancer(NSCLC)</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck (SCCHN)</condition>
  <arm_group>
    <arm_group_label>Tisotumab Vedotin (HuMax-TF-ADC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tisotumab Vedotin (HuMax-TF-ADC)</intervention_name>
    <arm_group_label>Tisotumab Vedotin (HuMax-TF-ADC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients with relapsed, advanced and/or metastatic cancer who have failed available&#xD;
        standard treatments or who are not candidates for standard therapy.&#xD;
&#xD;
        Patients must have measurable disease&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Acceptable renal function&#xD;
&#xD;
          -  Acceptable liver function&#xD;
&#xD;
          -  Acceptable hematological status (without hematologic support&#xD;
&#xD;
          -  Acceptable coagulation status&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Life expectancy of at least three months.&#xD;
&#xD;
          -  A negative serum pregnancy test (if female and aged between 18-55 years old).&#xD;
&#xD;
          -  Women who are pregnant or breast feeding are not to be included.&#xD;
&#xD;
          -  Patients, both females and males, of reproductive potential must agree to use adequate&#xD;
             contraception during and for six months after the last infusion of HuMax-TF-ADC.&#xD;
&#xD;
          -  Following receipt of verbal and written information about the study, patients must&#xD;
             provide signed informed consent before any study-related activity is carried out.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known past or current coagulation defects.&#xD;
&#xD;
          -  Ongoing major bleeding,&#xD;
&#xD;
          -  Have clinically significant cardiac disease&#xD;
&#xD;
          -  A baseline QT interval as corrected by Fridericia's formula (QTcF) &gt; 450 msec, a&#xD;
             complete left bundle branch block (defined as a QRS interval ≥ 120 msec in left bundle&#xD;
             branch block form) or an incomplete left bundle branch block.&#xD;
&#xD;
          -  Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage&#xD;
             colony stimulating factor support within one week or pegylated G-CSF within two weeks&#xD;
             before the Screening Visit.&#xD;
&#xD;
          -  Have received a cumulative dose of corticosteroid ≥ 100 mg (prednisone or equivalent&#xD;
             doses of corticosteroids) within two weeks before the first infusion.&#xD;
&#xD;
          -  Major surgery within six weeks or open biopsy within 14 days before drug infusion.&#xD;
&#xD;
          -  Plan for any major surgery during treatment period.&#xD;
&#xD;
          -  Any history of intracerebral arteriovenous malformation, cerebral aneurysm, brain&#xD;
             metastases or stroke.&#xD;
&#xD;
          -  Any anticancer therapy including; small molecules, immunotherapy, chemotherapy&#xD;
             monoclonal antibodies or any other experimental drug within four weeks or five half&#xD;
             lives, whichever is longest, before first infusion.&#xD;
&#xD;
          -  Prior treatment with bevacizumab within twelve weeks before the first infusion.&#xD;
&#xD;
          -  Radiotherapy within 28 days prior to first dose.&#xD;
&#xD;
          -  Patients who have not recovered from symptomatic side effects of radiotherapy at the&#xD;
             time of initiation of screening procedure.&#xD;
&#xD;
          -  Known past or current malignancy other than inclusion diagnosis, except for:&#xD;
&#xD;
          -  Cervical carcinoma of Stage 1B or less.&#xD;
&#xD;
          -  Non-invasive basal cell or squamous cell skin carcinoma.&#xD;
&#xD;
          -  Non-invasive, superficial bladder cancer.&#xD;
&#xD;
          -  Prostate cancer with a current PSA level &lt; 0.1 ng/mL.&#xD;
&#xD;
          -  Any curable cancer with a complete response (CR) of &gt; 5 years duration.&#xD;
&#xD;
          -  Known human immunodeficiency virus seropositivity.&#xD;
&#xD;
          -  Positive serology (unless due to vaccination or passive immunization due to Ig&#xD;
             therapy) for hepatitis B&#xD;
&#xD;
          -  Positive serology for hepatitis C based on test at screening.&#xD;
&#xD;
          -  Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.&#xD;
&#xD;
          -  Inflammatory lung disease including moderate and severe asthma and chronic obstructive&#xD;
             pulmonary disease (COPD) requiring chronic medical therapy.&#xD;
&#xD;
          -  Ongoing acute or chronic inflammatory skin disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johann de Bono, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Institute of Cancer Research &amp; The Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Irvine Medical Center (UCIMC)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecologic Oncology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <state>Hainaut</state>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur - site Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Luc University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur - Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <state>Solna</state>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungemedicinska Kliniken</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Newcastle</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre NHS Trust</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sørensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Mar;20(3):383-393. doi: 10.1016/S1470-2045(18)30859-3. Epub 2019 Feb 8. Erratum in: Lancet Oncol. 2019 Dec;20(12):e663.</citation>
    <PMID>30745090</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 14, 2013</study_first_submitted>
  <study_first_submitted_qc>November 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <disposition_first_submitted>April 21, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 21, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 24, 2020</disposition_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovary cancer</keyword>
  <keyword>cervix cancer</keyword>
  <keyword>endometrium cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>prostate cancer (CRPC)</keyword>
  <keyword>esophagus cancer</keyword>
  <keyword>lung cancer(NSCLC)</keyword>
  <keyword>Squamous cell carcinoma of the head and neck (SCCHN)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tisotumab vedotin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 6, 2021</submitted>
    <returned>November 5, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

